

Supporting Information

Enantioselective access to spiro[2,3-dihydrofuran-2,2'-inden-1-ones] via zinc catalyzed [3 + 2] annulation of α -hydroxy-1-indanones with yne-enones

Jiao-Jiao Han, Tao Jiang, Cui Zhang, Dan-Dan Cui, Yuan-Zhao Hua,* Guang-Jian Mei, Min-Can Wang,* and Shi-Kun Jia*

College of Chemistry and Institute of Green Catalysis, Zhengzhou University, Zhengzhou City, Henan 450000, P. R. China

Email: hyzhao@zzu.edu.cn, wangmincan@zzu.edu.cn, jiashikun@zzu.edu.cn

Table of Contents

1. General Information	S2
2. General Procedure for optimization of the reaction conditions	S2
3. Synthesis of enantioenriched 3	S2
4. Scale-up reaction	S16
5. The late-stage functionalization	S17
6. Derivatization	S18
7. References	S21
8. NMR Spectra	S22
9. HPLC	S63
10. Single-crystal X-ray diffraction	S101

General Information

All reactions were carried out under an atmosphere of argon using oven-dried glassware. Super dry solvents, metal catalysts, were purchased from chemical companies and used without further treatment. Flash column chromatography was performed using silica gel (300-400 mesh). ¹H NMR, ¹³C NMR, ¹⁹F NMR spectra were recorded in CDCl₃ or DMSO-d₆ on a 400 MHz spectrometer; chemical shifts are reported in ppm with the solvent signals as reference, and coupling constants (*J*) are given in Hertz. The peak information is described as: s = singlet, d = doublet, t = triplet, q = quartet, m= multiplet. High-resolution mass spectra (HRMS) were obtained using an Agilent LC-MSAD-Trap-XCT instrument using electrospray ionization time-of-flight (ESI-TOF). High performance liquid chromatography (HPLC) was performed on instrument consisted of JASCO model PU-1580 intelligent HPLC pump and JASCO model UV-1575 intelligent UV-vis detector (254 nm) using Daicel Chiralpak IC, ID (4.6 mm × 250 mm) columns. Melting points were determined using YRT-3 melting point apparatus. Optical rotations were measured with Perkin Elmer, model 341 Polarimeter. The instrumentation used for the crystal measurement is Oxford Gemini E X-ray single-crystal diffractometer. α -Hydroxy-1-indanones¹ and yne-enones² were synthesized according to the literature.


General Procedure for optimization of the reaction conditions

Under a nitrogen atmosphere, a solution of diethylzinc (20 μ L, 1.0 M in hexane, 0.02 mmol, 0.2 eq) was added dropwise to a solution of **L** (0.01 mmol, 0.1 eq) in solvent (2 mL). After the mixture was stirred for 30 min at 40 °C, then, α -hydroxy-1-indanone **1a** (0.1 mmol, 14.8 mg, 1.0 eq), yne-enone **2a** (0.1 mmol, 24.6 mg, 1.0 eq), and additives were added. The reaction mixture was stirred for 48 h at the same temperature. The reaction was quenched with NH₄Cl solution (2 mL), and the aqueous layer was extracted with CH₂Cl₂ (3 × 5 mL). The combined organic layer was washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure by using a rotary evaporator. The residue was purified by flash chromatography with petroleum ether/ethyl acetate (4/1) to afford the desired product **3a**.

Synthesis of chiral spiro[2,3-dihydrofuran-2,2'-inden-1-ones]

Under a nitrogen atmosphere, a solution of diethylzinc (40 μ L, 1.0 M in hexane, 0.04 mmol, 0.2 eq) was added dropwise to a solution of **L1** (0.02 mmol, 14.0 mg, 0.1 eq) in toluene (2 mL). After the mixture was stirred for 30 min at 40 °C. Then, α -hydroxy-1-indanone **1a** (0.2 mmol, 29.6 mg, 1.0 eq), yne-enone **2a** (0.2 mmol, 49.2 mg, 1.0 eq) and 2-Br-4-ClPhOH (0.04 mmol, 8.28 mg, 0.2 eq) were added. The reaction mixture was stirred for 48 h at 40 °C. The reaction was quenched with NH₄Cl solution (4 mL), and the aqueous layer was extracted with CH₂Cl₂ (3 × 5 mL). The combined organic layer was washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure by using a rotary evaporator. The residue was purified by flash chromatography with petroleum ether/ethyl acetate (4/1) to afford the desired product **3a**.

(2*R*,3*R*)-4-acetyl-5-benzyl-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (**3a**):




3a

Followed the general procedure, using **1a** (0.2 mmol, 29.6 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.1 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1)

to afforded **3a** as a light yellow oil (54.2 mg, 65% yield, >20:1 dr); $[\alpha]_D^{20} = -152.8$ ($c = 2.0$, DCM, 98% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.82 – 7.64 (m, 1H), 7.49 – 7.40 (m, 1H), 7.38 – 7.13 (m, 9H), 7.09 – 7.02 (m, 1H), 6.90 (s, 2H), 4.48 (s, 1H), 4.12 (dd, $J = 92.8, 14.2$ Hz, 2H), 2.72 (dd, $J = 96.5, 17.6$ Hz, 2H), 1.82 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.5, 194.6, 169.4, 150.7, 139.4, 136.4, 136.0, 133.3, 129.1, 129.0, 128.5, 128.2, 128.0, 126.7, 126.3, 125.3, 116.0, 93.1, 53.8, 36.2, 34.2, 29.8; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₇H₂₂NaO₃]⁺: 417.1461, found: 417.1462; **HPLC**: Daicel Chiraldak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 21.87 min and t_{minor} = 10.83 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-5'-fluoro-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3b):



3b

Followed the general procedure, using **1b** (0.2 mmol, 33.4 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.2 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3b** as a light yellow oil (67.9 mg, 78% yield, >20:1 dr); $[\alpha]_D^{20} = -133.8$ ($c = 2.0$, DCM, 97% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.88 – 7.78 (m, 1H), 7.43 – 7.37 (m, 2H), 7.35 – 7.27 (m, 5H), 7.26 – 7.21 (m, 1H), 7.12 – 7.06 (m, 1H), 6.99 (s, 2H), 6.86 – 6.79 (m, 1H), 4.57 (s, 1H), 4.20 (dd, $J = 92.2, 14.4$ Hz, 2H), 2.79 (dd, $J = 94.1, 17.9$ Hz, 2H), 1.92 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 198.7, 194.6, 169.2, 167.8(d, $J = 258.7$ Hz), 153.7 (d, $J = 10.5$ Hz), 139.2, 136.3, 129.6 (d, $J = 1.8$ Hz), 129.2, 129.0, 128.5, 128.1, 127.8 (d, $J = 10.6$ Hz), 126.8, 116.6 (d, $J = 23.8$ Hz), 116.0, 113.2 (d, $J = 22.6$ Hz), 93.1, 53.9, 36.2, 34.2, 29.8; **19F NMR** (376 MHz, CDCl₃) δ -99.7; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₇H₂₁FNaO₃]⁺: 435.1367, found: 435.1375; **HPLC**: Daicel Chiraldak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 21.35 min and t_{minor} = 11.26 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-5'-chloro-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3c):



3c

Followed the general procedure, using **1c** (0.2 mmol, 36.4 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3c** as a light yellow oil (57.7 mg, 64% yield, >20:1 dr); $[\alpha]_D^{20} = -164.6$ ($c = 1.0$, DCM, 98% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.74 (d, $J = 8.2$ Hz, 1H), 7.44 – 7.35 (m, 3H), 7.35 – 7.29 (m, 4H), 7.29 – 7.21 (m, 2H), 7.16 (s, 1H), 6.99 (s, 2H), 4.56 (s, 1H), 4.20 (dd, $J = 90.6, 14.3$ Hz, 2H), 2.78 (dd, $J = 95.0, 17.9$ Hz, 2H), 1.91 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 199.1, 194.6, 169.3, 152.3, 142.6, 139.1, 136.3, 131.7, 129.2, 129.1, 129.0, 128.5, 128.1, 126.8, 126.5, 126.4, 116.0, 93.0, 53.8, 36.0, 34.1, 29.8; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₇H₂₁ClNaO₃]⁺: 451.1071, found: 451.1078; **HPLC**: Daicel Chiraldak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 22.86 min and t_{minor} = 11.50 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-5'-bromo-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3d):



3d

Followed the general procedure, using **1d** (0.2 mmol, 45.4 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3d** as a light yellow oil (64.4 mg, 65% yield, >20:1 dr); $[\alpha]_D^{20} = -123.4$ ($c = 2.0$, DCM, 98% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.66 (d, $J = 8.2$ Hz, 1H), 7.55 – 7.50 (m, 1H), 7.40 (d, $J = 7.2$ Hz, 2H), 7.36 – 7.27 (m, 6H), 7.26 – 7.22 (m, 1H), 7.05 – 6.92 (m, 2H), 4.55 (s, 1H), 4.19 (dd, $J = 90.0, 14.3$ Hz, 2H), 2.78 (dd, $J = 94.4, 17.9$ Hz, 2H), 1.91 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 199.3, 194.6, 169.2, 152.2, 139.1, 136.3, 132.1, 132.0, 131.6, 129.6, 129.2, 129.0, 128.6, 128.1, 126.8, 126.5, 116.0, 92.9, 53.8, 35.9, 34.2, 29.8; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₇H₂₁BrNaO₃]⁺: 495.0566, found: 495.0569; **HPLC**: Daicel Chiraldak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 29.59 min and t_{minor} = 14.15 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-5'-methyl-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3e):



3e

Followed the general procedure, using **1e** (0.2 mmol, 32.2 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3e** as a light yellow oil (63.0 mg, 73% yield, >20:1 dr); $[\alpha]_D^{20} = -191.3$ ($c = 2.0$, DCM, 94% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.70 (d, $J = 7.9$ Hz, 1H), 7.45 – 7.39 (m, 2H), 7.36 – 7.23 (m, 6H), 7.19 (d, $J = 7.9$ Hz, 1H), 7.09 – 6.88 (m, 3H), 4.56 (s, 1H), 4.20 (dd, $J = 101.6, 14.3$ Hz, 2H), 2.75 (dd, $J = 95.1, 17.7$ Hz, 2H), 2.37 (s, 3H), 1.90 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.0, 194.7, 169.4, 151.2, 147.6, 139.5, 136.4, 130.9, 129.5, 129.1, 129.0, 128.5, 127.9, 126.7, 126.6, 125.2, 116.0, 93.3, 53.9, 36.1, 34.2, 29.8, 22.2; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₈H₂₄NaO₃]⁺: 431.1618, found: 431.1623; **HPLC**: Daicel Chiraldak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 32.91 min and t_{minor} = 12.82 min.

(2*R*,3*R*)-4-acetyl-5-benzyl-5'-methoxy-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3f):




3f

Followed the general procedure, using **1f** (0.2 mmol, 35.4 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3f** as a light yellow oil (57.2 mg, 64% yield, >20:1 dr); $[\alpha]_D^{20} = -182.1$ ($c = 2.0$, DCM, 98% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.66 (d, $J = 8.6$ Hz, 1H), 7.34 (d, $J = 7.4$ Hz, 2H), 7.26 – 7.22 (m, 2H), 7.21 – 7.12 (m, 4H), 7.01 – 6.86 (m, 2H), 6.85 – 6.80 (m, 1H), 6.55 – 6.45 (m, 1H), 4.51 (s, 1H), 4.12 (dd, $J = 107.5, 14.3$ Hz, 2H), 3.72 (s, 3H), 2.67 (dd, $J = 89.9, 17.8$ Hz, 2H), 1.82 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 198.6, 194.7, 169.4, 166.3, 153.9, 139.6, 136.5, 129.1, 129.0,

128.5, 127.8, 127.1, 126.7, 126.2, 116.2, 116.0, 109.5, 93.4, 55.7, 53.9, 36.4, 34.2, 29.8; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₈H₂₄NaO₄]⁺: 447.1567, found: 447.1568; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, t_{major} = 61.12 min and t_{minor} = 22.59 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-6'-fluoro-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3g):



3g

Followed the general procedure, using **1g** (0.2 mmol, 33.0 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afford **3g** as a light yellow oil (60.9 mg, 70% yield, >20:1 dr); $[\alpha]_D^{20} = -102.4$ (c = 2.0, DCM, 98% ee); **¹H NMR** (400 MHz, CDCl₃) δ 7.47 – 7.43 (m, 1H), 7.41 (d, J = 7.3 Hz, 2H), 7.36 – 7.26 (m, 6H), 7.26 – 7.22 (m, 1H), 7.16 – 7.11 (m, 1H), 7.07 – 6.90 (m, 2H), 4.55 (s, 1H), 4.20 (dd, J = 82.3, 14.4 Hz, 2H), 2.77 (dd, J = 96.3, 17.4 Hz, 2H), 1.92 (s, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 199.7 (d, J = 2.7 Hz), 194.6, 169.3, 162.6 (d, J = 249.5 Hz), 146.2, 139.1, 136.3, 135.0 (d, J = 7.4 Hz), 129.2, 129.0, 128.6, 128.1, 127.8 (d, J = 7.8 Hz), 126.8, 123.7 (d, J = 23.6 Hz), 116.0, 111.1 (d, J = 22.1 Hz), 93.6, 53.8, 35.7, 34.2, 29.8; **¹⁹F NMR** (376 MHz, CDCl₃) δ -112.6; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₇H₂₁FNaO₃]⁺: 435.1367, found: 435.1370; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, t_{major} = 19.81 min and t_{minor} = 13.21 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-6'-chloro-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3h):



3h

Followed the general procedure, using **1h** (0.2 mmol, 36.5 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afford **3h** as a light yellow oil (67.7 mg, 75% yield, >20:1 dr); $[\alpha]_D^{20} = -132.2$ (c = 3.0, DCM, 98% ee); **¹H NMR** (400 MHz, CDCl₃) δ 7.81 – 7.71 (m, 1H), 7.53 – 7.48 (m, 1H), 7.40 (d, J = 7.4 Hz, 2H), 7.36 – 7.29 (m, 4H), 7.28 – 7.21 (m, 2H), 7.10 (d, J = 8.2 Hz, 1H), 7.06 – 6.87 (m, 2H), 4.54 (s, 1H), 4.20 (dd, J = 84.0, 14.4 Hz, 2H), 2.77 (dd, J = 96.7, 17.7 Hz, 2H), 1.92 (s, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 199.3, 194.6, 169.2, 148.8, 139.1, 136.2, 136.0, 134.8, 134.6, 129.2, 129.0, 128.6, 128.1, 127.6, 126.8, 125.0, 116.0, 93.3, 53.8, 35.8, 34.1, 29.8; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₇H₂₁ClNaO₃]⁺: 451.1071, found: 451.1078; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, t_{major} = 21.44 min and t_{minor} = 12.64 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-6'-bromo-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3i):



3i

Followed the general procedure, using **1i** (0.2 mmol, 45.2 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3i** as a light yellow oil (59.4 mg, 60% yield, >20:1 dr); $[\alpha]_D^{20} = -115.7$ ($c = 2.0$, DCM, 98% ee); **¹H NMR** (400 MHz, CDCl₃) δ 7.97 – 7.86 (m, 1H), 7.68 – 7.61 (m, 1H), 7.40 (d, $J = 7.3$ Hz, 2H), 7.35 – 7.27 (m, 5H), 7.26 – 7.22 (m, 1H), 7.05 (d, $J = 8.1$ Hz, 1H), 7.03 – 6.84 (m, 2H), 4.54 (s, 1H), 4.20 (dd, $J = 84.9, 14.4$ Hz, 2H), 2.74 (dd, $J = 96.3, 17.8$ Hz, 2H), 1.91 (s, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 199.1, 194.6, 169.2, 149.2, 139.0, 138.8, 136.2, 135.1, 129.2, 129.0, 128.6, 128.1, 128.1, 127.9, 126.8, 122.3, 116.0, 93.2, 53.8, 35.9, 34.1, 29.8; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₇H₂₁BrNaO₃]⁺: 495.0566, found: 495.0573; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 25.41 min and t_{minor} = 13.54 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-6'-methyl-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3j):



3j

Followed the general procedure, using **1j** (0.2 mmol, 32.2 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3j** as a light yellow oil (68.1 mg, 79% yield, >20:1 dr); $[\alpha]_D^{20} = -155.3$ ($c = 1.7$, DCM, 99% ee); **¹H NMR** (400 MHz, CDCl₃) δ 7.59 (s, 1H), 7.44 – 7.39 (m, 2H), 7.39 – 7.26 (m, 6H), 7.26 – 7.21 (m, 1H), 7.05 (d, $J = 7.8$ Hz, 1H), 7.03 – 6.85 (m, 2H), 4.55 (s, 1H), 4.21 (dd, $J = 95.8, 14.3$ Hz, 2H), 2.75 (dd, $J = 99.5, 17.5$ Hz, 2H), 2.39 (s, 3H), 1.91 (s, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 200.6, 194.7, 169.5, 148.1, 139.4, 138.3, 137.3, 136.4, 133.4, 129.1, 129.0, 128.5, 127.9, 126.7, 126.0, 125.2, 115.9, 93.5, 53.8, 35.9, 34.2, 29.8, 21.2; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₈H₂₄NaO₃]⁺: 431.1618, found: 431.1628; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 33.75 min and t_{minor} = 12.19 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-6'-methoxy-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3k):



3k


Followed the general procedure, using **1k** (0.2 mmol, 35.4 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3k** as a light yellow oil (58.1 mg, 65% yield, >20:1 dr); $[\alpha]_D^{20} = -227.2$ ($c = 1.0$, DCM, 98% ee); **¹H NMR** (400 MHz, CDCl₃) δ 7.42 (d, $J = 7.4$ Hz, 2H), 7.35 – 7.26 (m, 5H), 7.25 – 7.18 (m, 2H), 7.16 – 7.12 (m, 1H), 7.04 (d, $J = 8.4$ Hz, 1H), 7.03 – 6.84 (m, 2H), 4.55 (s, 1H), 4.21 (dd, $J = 86.3, 14.3$ Hz, 2H), 3.83 (s, 3H), 2.73 (dd, $J = 97.8, 17.3$ Hz, 2H), 1.91 (s, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 200.5, 194.6, 169.5, 159.9, 143.6, 139.4, 136.4, 134.4, 129.1, 129.0, 128.5, 127.9, 127.1, 126.7, 125.4, 115.9, 106.4, 93.8, 55.7, 53.9, 35.6, 34.2, 29.8; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₈H₂₄NaO₄]⁺: 447.1567, found: 447.1575; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 45.15 min and t_{minor} = 14.44 min.

(2*R*,3*R*)-4-acetyl-5-benzyl-4'-chloro-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3*H*)-one (3l):




Followed the general procedure, using **1l** (0.2 mmol, 36.5 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3l** as a light yellow oil (58.6 mg, 65% yield, >20:1 dr); $[\alpha]_D^{20} = -104.0$ ($c = 2.0$, DCM, 99% ee); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.72 (d, $J = 7.5$ Hz, 1H), 7.55 (d, $J = 7.7$ Hz, 1H), 7.45 – 7.38 (m, 2H), 7.38 – 7.28 (m, 6H), 7.27 – 7.22 (m, 1H), 7.08 – 6.87 (m, 2H), 4.57 (s, 1H), 4.20 (dd, $J = 85.1$, 14.4 Hz, 2H), 2.79 (dd, $J = 91.4$, 18.2 Hz, 2H), 1.93 (s, 3H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 199.7, 194.6, 169.1, 148.4, 138.9, 136.2, 135.6, 135.2, 132.6, 129.7, 129.3, 129.0, 128.6, 128.2, 126.8, 123.5, 116.0, 92.8, 53.8, 35.2, 34.1, 29.8, 29.7; **HRMS** (ESI): m/z [M + Na] $^+$ calcd for $[\text{C}_{27}\text{H}_{21}\text{ClNaO}_3]^+$: 451.1071, found: 451.1073; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, $t_{\text{major}} = 21.23$ min and $t_{\text{minor}} = 11.20$ min.

(2*R*,3*R*)-4-acetyl-5-benzyl-4'-bromo-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3*H*)-one (3m):



Followed the general procedure, using **1m** (0.2 mmol, 45.2 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3m** as a light yellow oil (62.4 mg, 63% yield, >20:1 dr); $[\alpha]_D^{20} = -172.2$ ($c = 2.0$, DCM, 99% ee); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.79 – 7.68 (m, 2H), 7.40 (d, $J = 7.4$ Hz, 2H), 7.37 – 7.27 (m, 6H), 7.26 – 7.22 (m, 1H), 7.09 – 6.85 (m, 2H), 4.56 (s, 1H), 4.21 (dd, $J = 83.0$, 14.4 Hz, 2H), 2.74 (dd, $J = 94.7$, 18.1 Hz, 2H), 1.92 (s, 3H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 199.9, 194.6, 169.2, 150.4, 138.8, 138.7, 136.2, 135.3, 129.9, 129.3, 129.0, 128.6, 128.2, 126.8, 124.1, 121.8, 116.0, 92.8, 53.8, 37.2, 34.2, 29.8; **HRMS** (ESI): m/z [M + Na] $^+$ calcd for $[\text{C}_{27}\text{H}_{21}\text{BrNaO}_3]^+$: 495.0566, found: 495.0573; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, $t_{\text{major}} = 22.90$ min and $t_{\text{minor}} = 11.81$ min.


(2*R*,3*R*)-4-acetyl-5-benzyl-4'-methyl-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3*H*)-one (3n):



Followed the general procedure, using **1n** (0.2 mmol, 32.2 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3n** as a light yellow oil (58.6 mg, 68% yield, >20:1 dr); $[\alpha]_D^{20} = -145.0$ ($c = 2.0$, DCM, 96% ee); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.66 (d, $J = 7.4$ Hz, 1H), 7.43 (d, $J = 7.4$ Hz, 2H), 7.38 – 7.26 (m, 7H), 7.25 – 7.21 (m, 1H), 7.09 – 6.81 (m, 2H), 4.55 (s, 1H), 4.22 (dd, $J = 102.9$, 14.3 Hz, 2H), 2.67 (dd, $J = 97.0$, 17.5 Hz, 2H), 2.00 (s, 3H), 1.91 (s, 3H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ

200.9, 194.7, 169.6, 149.6, 139.3, 136.5, 136.4, 135.6, 133.1, 129.1, 129.0, 128.5, 128.3, 128.0, 126.7, 122.7, 115.7, 93.3, 54.0, 34.8, 34.2, 29.8, 17.6; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₈H₂₄NaO₃]⁺: 431.1618, found: 431.1626; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, t_{major} = 33.90 min and t_{minor} = 14.63 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-4'-methoxy-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3o):



3o

Followed the general procedure, using **1o** (0.2 mmol, 35.4 mg), **2a** (0.2 mmol, 49.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3o** as a light yellow oil (66.2 mg, 74% yield, >20:1 dr); $[\alpha]_D^{20} = -283.3$ (c = 2.0, DCM, 97% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.40 (d, *J* = 7.8 Hz, 3H), 7.37 – 7.26 (m, 6H), 7.25 – 7.20 (m, 1H), 7.08 – 6.95 (m, 3H), 4.59 (s, 1H), 4.18 (dd, *J* = 107.2, 14.3 Hz, 2H), 3.72 (s, 3H), 2.73 (dd, *J* = 80.7, 18.2 Hz, 2H), 1.91 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.7, 194.7, 169.1, 156.5, 139.8, 139.4, 136.4, 134.6, 129.7, 129.1, 129.0, 128.5, 127.9, 126.7, 116.7, 116.3, 116.3, 92.9, 55.4, 53.6, 34.2, 33.1, 29.8; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₈H₂₄NaO₄]⁺: 447.1567, found: 447.1567; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, t_{major} = 31.25 min and t_{minor} = 14.12 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-3-(4-chlorophenyl)-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3p):



3p


Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2b** (0.2 mmol, 56.3 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3p** as a light yellow oil (67.7 mg, 75% yield, >20:1 dr); $[\alpha]_D^{20} = -230.0$ (c = 2.3, DCM, 98% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.81 (d, *J* = 7.6 Hz, 1H), 7.61 – 7.53 (m, 1H), 7.46 – 7.37 (m, 3H), 7.37 – 7.30 (m, 2H), 7.29 – 7.22 (m, 3H), 7.19 (d, *J* = 7.6 Hz, 1H), 7.01 – 6.82 (m, 2H), 4.54 (s, 1H), 4.19 (dd, *J* = 88.6, 14.4 Hz, 2H), 2.82 (dd, *J* = 110.0, 17.6 Hz, 2H), 1.95 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.1, 194.1, 169.6, 150.4, 138.0, 136.2, 133.8, 133.2, 129.6, 129.3, 129.0, 128.6, 128.4, 126.8, 126.3, 125.4, 116.1, 92.9, 53.1, 36.1, 34.2, 29.7; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₇H₂₁ClNaO₃]⁺: 451.1071, found: 451.1075; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, t_{major} = 22.83 min and t_{minor} = 11.71 min.

(2*R*,3*R*)-4-acetyl-5-benzyl-3-(*p*-tolyl)-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3q):




Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2c** (0.2 mmol, 52.0 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afford **3q** as a light yellow oil (70.7 mg, 82% yield, >20:1 dr); $[\alpha]_D^{20} = -254.2$ ($c = 2.8$, DCM, 96% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.80 (d, $J = 7.6$ Hz, 1H), 7.57 – 7.50 (m, 1H), 7.44 – 7.35 (m, 3H), 7.34 – 7.28 (m, 2H), 7.24 (d, $J = 6.3$ Hz, 1H), 7.16 (d, $J = 7.7$ Hz, 1H), 7.13 – 7.03 (m, 2H), 6.96 – 6.77 (m, 2H), 4.52 (s, 1H), 4.20 (dd, $J = 91.9, 14.3$ Hz, 2H), 2.82 (dd, $J = 82.4, 17.6$ Hz, 2H), 2.32 (s, 3H), 1.91 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.6, 194.8, 169.3, 150.8, 137.7, 136.5, 136.3, 136.0, 133.3, 129.8, 129.0, 128.5, 128.2, 126.7, 126.3, 125.3, 116.0, 93.2, 53.5, 36.2, 34.2, 29.8, 21.2; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₈H₂₄NaO₃]⁺: 431.1618, found: 431.1626; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, $t_{\text{major}} = 25.04$ min and $t_{\text{minor}} = 12.90$ min.

(2*R*,3*R*)-4-acetyl-5-benzyl-3-(3-chlorophenyl)-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3r):



Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2d** (0.2 mmol, 56.3 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afford **3r** as a light yellow oil (72.2 mg, 80% yield, >20:1 dr); $[\alpha]_D^{20} = -216.6$ ($c = 4.0$, DCM, 96% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.81 (d, $J = 7.7$ Hz, 1H), 7.60 – 7.54 (m, 1H), 7.46 – 7.37 (m, 3H), 7.37 – 7.30 (m, 2H), 7.28 – 7.18 (m, 4H), 7.06 – 6.78 (m, 2H), 4.53 (s, 1H), 4.20 (dd, $J = 91.1, 14.4$ Hz, 2H), 2.82 (dd, $J = 115.3, 17.7$ Hz, 2H), 1.97 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.0, 194.0, 169.7, 169.4, 150.5, 141.7, 136.2, 136.1, 133.1, 130.4, 128.9, 128.6, 128.4, 128.2, 126.9, 126.3, 125.4, 116.0, 92.9, 53.3, 36.2, 34.2, 29.8; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₇H₂₁ClNaO₃]⁺: 451.1071, found: 451.1072; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, $t_{\text{major}} = 21.49$ min and $t_{\text{minor}} = 10.85$ min.


(2*R*,3*R*)-4-acetyl-5-benzyl-3-(3-methoxyphenyl)-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3s):



Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2e** (0.2 mmol, 55.2 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1)

to afforded **3s** as a light yellow oil (63.5 mg, 71% yield, >20:1 dr); $[\alpha]_D^{20} = -265.0$ ($c = 3.0$, DCM, 97% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.82 (d, $J = 7.7$ Hz, 1H), 7.60 – 7.52 (m, 1H), 7.48 – 7.35 (m, 3H), 7.35 – 7.27 (m, 2H), 7.27 – 7.16 (m, 3H), 6.83 – 6.76 (m, 1H), 6.75 – 6.26 (m, 2H), 4.52 (s, 1H), 4.20 (dd, $J = 151.6, 13.3$ Hz, 2H), 3.62 (s, 3H), 2.83 (dd, $J = 89.7, 17.7$ Hz, 2H), 1.93 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.5, 194.7, 169.5, 150.9, 141.0, 136.6, 136.0, 133.2, 130.1, 129.1, 128.5, 128.2, 126.7, 126.3, 125.4, 115.7, 93.1, 55.1, 53.7, 36.2, 34.2, 29.8; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₈H₂₄NaO₄]⁺: 447.1567, found: 447.1574; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 33.41 min and t_{minor} = 14.05 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-3-(2-chlorophenyl)-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3t):



3t

Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2f** (0.2 mmol, 56.3 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3t** as a light yellow oil (58.6 mg, 65% yield, 6:1 dr); $[\alpha]_D^{20} = -109.8$ ($c = 3.0$, DCM, 89% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.82 (d, $J = 7.7$ Hz, 1H), 7.59 – 7.54 (m, 1H), 7.43 – 7.38 (m, 3H), 7.35 – 7.29 (m, 3H), 7.27 – 7.18 (m, 4H), 7.15 – 7.10 (m, 1H), 5.24 (s, 1H), 4.20 (dd, $J = 97.7, 14.3$ Hz, 2H), 2.79 (dd, $J = 94.9, 17.8$ Hz, 2H), 1.91 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.0, 194.5, 169.8, 150.9, 137.2, 136.3, 136.1, 134.3, 133.1, 129.8, 129.4, 129.1, 129.0, 128.6, 128.2, 127.7, 126.8, 126.2, 125.4, 115.1, 92.6, 49.2, 36.4, 34.2, 29.5; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₇H₂₁ClNaO₃]⁺: 451.1071, found: 451.1078; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 15.07 min and t_{minor} = 11.42 min.

(2*R*,3*R*)-4-acetyl-5-benzyl-3-(2-methoxyphenyl)-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3u):




3u

Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2g** (0.2 mmol, 55.2 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3u** as a light yellow oil (51.0 mg, 57% yield, >20:1 dr); $[\alpha]_D^{20} = -70.6$ ($c = 2.0$, DCM, 89% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.83 (d, $J = 7.6$ Hz, 1H), 7.55 – 7.51 (m, 1H), 7.42 (d, $J = 7.3$ Hz, 2H), 7.40 – 7.36 (m, 1H), 7.33 – 7.29 (m, 2H), 7.26 – 7.21 (m, 2H), 7.14 (d, $J = 7.6$ Hz, 1H), 7.06 – 7.03 (m, 1H), 6.93 (t, $J = 7.4$ Hz, 1H), 6.72 (d, $J = 8.1$ Hz, 1H), 5.13 (s, 1H), 4.19 (dd, $J = 107.2, 14.4$ Hz, 2H), 3.24 (s, 3H), 2.75 (dd, $J = 74.3, 17.7$ Hz, 2H), 1.92 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 201.3, 195.2, 169.4, 156.9, 151.2, 136.6, 135.6, 133.6, 129.0, 128.9, 128.5, 128.4, 127.8, 127.4, 126.6, 126.0, 125.0, 121.0, 114.2, 110.1, 92.8, 54.6, 46.9, 36.6, 34.2, 29.4; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₈H₂₄NaO₄]⁺: 447.1567, found: 447.1574; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 27.71 min and

$t_{\text{minor}} = 18.73 \text{ min.}$


(2*R*,3*R*)-4-acetyl-5-benzyl-3-(naphthalen-2-yl)-3*H*-spiro[furan-2,2'-inden]-1'(3'*H*)-one (3v):



3v

Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2h** (0.2 mmol, 59.2 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afford **3v** as a light yellow oil (68.2 mg, 73% yield, >20:1 dr); $[\alpha]_D^{20} = -280.7$ ($c = 3.0$, DCM, 93% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.87 – 7.76 (m, 3H), 7.70 – 7.65 (m, 1H), 7.54 – 7.44 (m, 6H), 7.40 – 7.33 (m, 3H), 7.30 – 7.25 (m, 1H), 7.20 – 6.93 (m, 2H), 4.73 (s, 1H), 4.26 (dd, $J = 115.1, 14.1$ Hz, 2H), 2.82 (dd, $J = 103.9, 17.7$ Hz, 2H), 1.92 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.5, 194.7, 169.6, 150.8, 136.9, 136.5, 136.1, 133.4, 133.2, 133.0, 129.1, 128.6, 128.3, 127.9, 127.8, 126.8, 126.6, 126.3, 125.4, 116.1, 93.1, 53.9, 36.3, 34.3, 29.9; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₃₁H₂₄NaO₃]⁺: 467.1618, found: 467.1616; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, $t_{\text{major}} = 28.91$ min and $t_{\text{minor}} = 13.78$ min.


(2*R*,3*R*)-4-acetyl-5-benzyl-3-(thiophen-2-yl)-3*H*-spiro[furan-2,2'-inden]-1'(3'*H*)-one (3w):



3w

Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2i** (0.2 mmol, 50.4 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afford **3w** as a light yellow oil (46.5 mg, 55% yield, 2.5:1 dr); $[\alpha]_D^{20} = -206.5$ ($c = 2.0$, DCM, 98%/98% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.86 – 7.73 (m, 1H), 7.62 – 7.55 (m, 1H), 7.43 – 7.36 (m, 3H), 7.35 – 7.29 (m, 3H), 7.27 – 7.22 (m, 2H), 6.99 – 6.94 (m, 1H), 6.72 (d, $J = 3.4$ Hz, 1H), 4.82 (s, 1H), 4.47 – 4.31 (m, 1H), 4.14 – 3.95 (m, 1H), 3.05 – 2.98 (m, 1H), 2.91 – 2.82 (m, 1H), 2.01 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.1, 194.3, 169.6, 150.8, 143.9, 136.3, 136.2, 133.2, 129.0, 128.5, 128.3, 127.5, 126.7, 126.4, 126.2, 125.8, 125.4, 116.2, 93.0, 48.7, 35.7, 34.2, 29.5; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₅H₂₀NaO₃S]⁺: 423.1025, found: 423.1029; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, major product: $t_{\text{major}} = 23.17$ min and $t_{\text{minor}} = 12.34$ min; minor product: $t_{\text{major}} = 20.17$ min and $t_{\text{minor}} = 11.43$ min.


(2*R*,3*R*)-5-benzyl-1'-oxo-3-phenyl-1',3'-dihydro-3*H*-spiro[furan-2,2'-indene]-4-carbaldehyde (3x):



3x


Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2j** (0.2 mmol, 46.4 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3x** as a light yellow oil (52.4 mg, 65% yield, >20:1 dr); $[\alpha]_D^{20} = -303.0$ ($c = 2.0$, DCM, 98% ee); **¹H NMR** (400 MHz, CDCl₃) δ 9.85 (s, 1H), 7.80 (d, $J = 7.7$ Hz, 1H), 7.58 – 7.52 (m, 1H), 7.41 – 7.34 (m, 5H), 7.31 – 7.28 (m, 1H), 7.26 – 7.22 (m, 3H), 7.16 (d, $J = 7.7$ Hz, 1H), 7.00 – 6.90 (m, 2H), 4.54 (s, 1H), 4.08 (dd, $J = 35.9, 15.1$ Hz, 2H), 2.86 (dd, $J = 101.7, 17.7$ Hz, 2H); **¹³C NMR** (101 MHz, CDCl₃) δ 200.1, 184.2, 174.5, 150.6, 138.2, 136.2, 135.0, 133.2, 128.9, 128.8, 128.8, 128.3, 128.1, 127.7, 127.4, 126.3, 125.4, 119.6, 94.4, 51.3, 35.8, 33.2; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₆H₂₀NaO₃]⁺: 403.1305, found: 403.1308; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, $t_{\text{major}} = 46.57$ min and $t_{\text{minor}} = 50.78$ min.

(2*R*,3*R*)-5-benzyl-3-phenyl-4-propionyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3y):



Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2k** (0.2 mmol, 52.0 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3y** as a light yellow oil (72.4 mg, 84% yield, 10:1 dr); $[\alpha]_D^{20} = -272.1$ ($c = 2.7$, DCM, 99%/92% ee); **¹H NMR** (400 MHz, CDCl₃) δ 7.81 (d, $J = 7.6$ Hz, 1H), 7.54 (t, $J = 7.1$ Hz, 1H), 7.46 – 7.41 (m, 2H), 7.38 (t, $J = 7.4$ Hz, 1H), 7.35 – 7.31 (m, 2H), 7.31 – 7.19 (m, 4H), 7.15 (d, $J = 7.7$ Hz, 1H), 7.08 – 6.86 (m, 2H), 4.57 (s, 1H), 4.35 (d, $J = 14.3$ Hz, 1H), 4.08 (d, $J = 14.3$ Hz, 1H), 2.92 (d, $J = 17.6$ Hz, 1H), 2.67 (d, $J = 17.7$ Hz, 1H), 2.47 – 2.32 (m, 1H), 1.98 – 1.84 (m, 1H), 0.89 (t, $J = 7.2$ Hz, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 200.5, 197.5, 168.9, 150.8, 139.5, 136.6, 136.0, 133.3, 129.7, 129.1, 128.5, 128.2, 127.9, 126.6, 126.3, 125.3, 115.6, 93.1, 53.4, 36.2, 34.6, 34.2, 7.6; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₈H₂₄NaO₃]⁺: 431.1618, found: 431.1621; **HPLC**: Daicel Chiralpak ID, *n*-hexane/*i*-PrOH = 80/20, flow rate = 1 mL/min, $\lambda = 254$ nm, major product: $t_{\text{major}} = 18.90$ min and $t_{\text{minor}} = 23.60$ min; minor product: $t_{\text{major}} = 17.56$ min and $t_{\text{minor}} = 13.62$ min.


(2*R*,3*R*)-5-benzyl-4-butryryl-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3z):



Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2l** (0.2 mmol, 54.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3z** as a light yellow oil (67.7 mg, 76% yield, 5:1 dr); $[\alpha]_D^{20} = -255.1$ ($c = 2.0$, DCM, 94%/53% ee); **¹H NMR** (400 MHz, CDCl₃) δ 7.81 (d, $J = 7.6$ Hz, 1H), 7.57 – 7.51 (m, 1H), 7.45 – 7.36 (m, 3H), 7.34 – 7.30 (m, 2H), 7.29 – 7.21 (m, 4H), 7.16 (d, $J = 7.6$ Hz, 1H), 7.10 – 6.84 (m, 2H), 4.58 (s, 1H), 4.33 (d, $J = 14.3$ Hz, 1H), 4.08 (d, $J = 14.3$ Hz, 1H), 2.80 (dd, $J = 97.3, 17.6$ Hz, 2H), 2.41 – 2.26 (m, 1H), 2.00 – 1.84 (m, 1H), 1.58 – 1.33 (m, 2H), 0.72 (t, $J = 7.4$ Hz, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 200.6, 197.1, 168.9, 150.8, 139.5, 136.6, 136.0, 133.3, 129.0, 129.0, 128.7, 128.5, 128.2, 127.9, 126.6, 126.3, 125.3, 115.8, 93.0, 53.5, 43.3, 36.2, 34.2, 17.1, 13.7; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₉H₂₆NaO₃]⁺: 445.1774, found: 445.1781; **HPLC**: Daicel


Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, major product: $t_{\text{major}} = 9.34$ min and $t_{\text{minor}} = 7.33$ min; minor product: $t_{\text{major}} = 6.03$ min and $t_{\text{minor}} = 8.75$ min.

(2*R*,3*R*)-4-benzoyl-5-benzyl-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'*H*)-one (3aa):




Followed the general procedure, using **1e** (0.2 mmol, 32.4 mg), **2m** (0.2 mmol, 61.3 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afford **3aa** as a light yellow oil (65.8 mg, 70% yield, >20:1 dr); $[\alpha]_D^{20} = -66.2$ ($c = 2.0$, DCM, 96% ee); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.72 (d, $J = 7.9$ Hz, 1H), 7.65 – 7.56 (m, 2H), 7.42 – 7.35 (m, 1H), 7.34 – 7.25 (m, 6H), 7.25 – 7.13 (m, 5H), 6.97 – 6.84 (m, 3H), 4.79 (s, 1H), 3.83 (dd, $J = 48.3, 14.9$ Hz, 2H), 2.83 (dd, $J = 77.9, 17.7$ Hz, 2H), 2.35 (s, 3H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 200.5, 192.5, 168.5, 151.5, 147.6, 140.5, 139.0, 136.2, 131.3, 131.1, 129.5, 129.0, 128.7, 128.5, 128.3, 127.9, 127.4, 126.7, 126.7, 125.1, 117.3, 93.2, 55.0, 35.9, 34.4, 22.2; **HRMS** (ESI): m/z [M + Na] $^+$ calcd for $[\text{C}_{33}\text{H}_{26}\text{NaO}_3]^+$: 493.1774, found: 493.1767; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, $t_{\text{major}} = 14.61$ min and $t_{\text{minor}} = 24.32$ min.

Methyl 3-(((2*R*,3*R*)-4-acetyl-1'-oxo-3-phenyl-1',3'-dihydro-3*H*-spiro[furan-2,2'-inden]-5-yl)methyl)benzoate (3ab):



Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2n** (0.2 mmol, 60.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afford **3ab** as a light yellow oil (67.5 mg, 71% yield, >20:1 dr); $[\alpha]_D^{20} = -253.5$ ($c = 3.0$, DCM, 96% ee); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.10 (s, 1H), 7.93 (d, $J = 7.7$ Hz, 1H), 7.81 (d, $J = 7.6$ Hz, 1H), 7.71 – 7.62 (m, 1H), 7.56 (t, $J = 7.4$ Hz, 1H), 7.45 – 7.37 (m, 2H), 7.35 – 7.26 (m, 3H), 7.21 – 7.15 (m, 1H), 7.11 – 6.88 (m, 2H), 4.57 (s, 1H), 4.26 (dd, $J = 77.0, 14.4$ Hz, 2H), 3.91 (s, 3H), 2.82 (dd, $J = 95.9, 17.6$ Hz, 2H), 1.90 (s, 3H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 200.3, 194.8, 168.6, 167.1, 150.7, 139.2, 136.8, 136.1, 133.6, 133.2, 130.4, 130.1, 129.2, 128.6, 128.3, 128.1, 128.0, 126.3, 125.4, 116.1, 93.2, 53.7, 52.1, 36.2, 33.9, 29.8; **HRMS** (ESI): m/z [M + Na] $^+$ calcd for $[\text{C}_{29}\text{H}_{24}\text{NaO}_5]^+$: 475.1516, found: 475.1520; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, $t_{\text{major}} = 42.66$ min and $t_{\text{minor}} = 25.21$ min.


(2*R*,3*R*)-4-acetyl-5-(4-ethylbenzyl)-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'*H*)-one (3ac):



Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2o** (0.2 mmol, 54.8 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1)

to afforded **3ac** as a light yellow oil (73.0 mg, 82% yield, >20:1 dr); $[\alpha]_D^{20} = -177.7$ ($c = 3.0$, DCM, 97% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.81 (d, $J = 7.7$ Hz, 1H), 7.57 – 7.52 (m, 1H), 7.42 – 7.36 (m, 1H), 7.35 – 7.31 (m, 2H), 7.30 – 7.24 (m, 3H), 7.18 – 7.12 (m, 3H), 7.07 – 6.86 (m, 2H), 4.57 (s, 1H), 4.17 (dd, $J = 92.4, 14.4$ Hz, 2H), 2.81 (dd, $J = 101.2, 17.8$ Hz, 2H), 2.66 – 2.58 (m, 2H), 1.91 (s, 3H), 1.23 (t, $J = 7.6$ Hz, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.5, 194.6, 169.7, 150.8, 142.6, 139.4, 136.0, 133.5, 133.3, 129.1, 128.9, 128.2, 128.0, 127.9, 126.3, 125.3, 116.0, 93.1, 53.8, 36.2, 33.8, 29.8, 28.5, 15.6; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₉H₂₆NaO₃]⁺: 445.1774, found: 445.1783; **HPLC**: Daicel Chiraldak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 26.14 min and t_{minor} = 14.55 min.


(2*R*,3*R*)-4-acetyl-5-(2-chlorobenzyl)-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3ad):



3ad

Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2p** (0.2 mmol, 56.3 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3ad** as a light yellow oil (72.2 mg, 80% yield, >20:1 dr); $[\alpha]_D^{20} = -246.2$ ($c = 3.0$, DCM, 95% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.80 (d, $J = 7.7$ Hz, 1H), 7.56 – 7.50 (m, 2H), 7.42 – 7.29 (m, 5H), 7.27 – 7.23 (m, 1H), 7.19 – 7.13 (m, 2H), 7.13 – 6.81 (m, 2H), 4.58 (s, 1H), 4.44 – 4.34 (m, 2H), 2.83 (dd, $J = 93.6, 17.7$ Hz, 2H), 1.92 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.6, 194.5, 168.1, 150.7, 139.3, 136.1, 134.2, 134.0, 133.2, 130.4, 129.3, 129.2, 128.2, 128.1, 128.0, 127.0, 126.3, 125.3, 117.0, 93.2, 53.9, 36.2, 32.1, 29.7; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₇H₂₁ClNaO₃]⁺: 451.1071, found: 451.1077; **HPLC**: Daicel Chiraldak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 21.77 min and t_{minor} = 11.16 min.


(2*R*,3*R*)-4-acetyl-3-phenyl-5-(thiophen-2-ylmethyl)-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3ae):



3ae


Followed the general procedure, using **1a** (0.2 mmol, 29.4 mg), **2q** (0.2 mmol, 50.4 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3ae** as a light yellow oil (58.4 mg, 69% yield, >20:1 dr); $[\alpha]_D^{20} = -285.8$ ($c = 2.0$, DCM, 97% ee); **1H NMR** (400 MHz, CDCl₃) δ 7.82 (d, $J = 7.7$ Hz, 1H), 7.58 – 7.53 (m, 1H), 7.42 – 7.38 (m, 1H), 7.35 – 7.26 (m, 3H), 7.20 – 7.16 (m, 2H), 7.13 – 6.97 (m, 3H), 6.96 – 6.93 (m, 1H), 4.58 (s, 1H), 4.38 (dd, $J = 139.2, 14.9$ Hz, 2H), 2.84 (dd, $J = 109.1, 17.7$ Hz, 2H), 1.90 (s, 3H); **13C NMR** (101 MHz, CDCl₃) δ 200.4, 194.6, 168.0, 150.8, 139.2, 137.8, 136.1, 133.3, 129.2, 128.3, 128.0, 126.8, 126.3, 126.3, 125.4, 124.4, 115.6, 93.3, 53.7, 36.3, 29.7, 28.7; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₂₅H₂₀NaO₃S]⁺: 423.1025, found: 423.1029; **HPLC**: Daicel Chiraldak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 30.73 min and t_{minor} = 13.43 min.

(2*R*,3*R*)-4-acetyl-5'-methyl-5-pentyl-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'H)-one (3af):



Followed the general procedure, using **1e** (0.2 mmol, 32.4 mg), **2r** (0.2 mmol, 45.4 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afford **3af** as a light yellow oil (42.7 mg, 55% yield, >20:1 dr); $[\alpha]_D^{20} = -156.8$ ($c = 2.0$, DCM, 96% ee); ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, $J = 7.9$ Hz, 1H), 7.31 – 7.18 (m, 3H), 7.14 (d, $J = 7.9$ Hz, 1H), 7.09 – 6.94 (m, 2H), 6.92 (s, 1H), 4.43 (s, 1H), 2.88 – 2.82 (m, 1H), 2.82 – 2.68 (m, 2H), 2.64 – 2.55 (m, 1H), 2.32 (s, 3H), 1.81 (s, 3H), 1.67 – 1.56 (m, 2H), 1.39 – 1.26 (m, 4H), 0.84 (t, $J = 7.1$ Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 199.0, 193.5, 171.5, 150.2, 146.5, 138.7, 129.9, 128.4, 128.0, 126.7, 125.6, 124.1, 114.4, 92.0, 52.7, 35.1, 30.6, 28.7, 27.3, 25.5, 21.3, 21.2, 13.0; HRMS (ESI): m/z [M + Na]⁺ calcd for [C₂₆H₂₈NaO₃]⁺: 411.1931, found: 411.1927; HPLC: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 20.38 min and t_{minor} = 8.37 min.


(2*R*,3*R*)-4-acetyl-5-benzyl-5'-bromo-3-(4-chlorophenyl)-3*H*-spiro[furan-2,2'-inden]-1'(3'*H*)-one (3ag):



3ag

Followed the general procedure, using **1d** (0.2 mmol, 45.2 mg), **2b** (0.2 mmol, 56.4 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afford **3ag** as a light yellow oil (79.4 mg, 75% yield, >20:1 dr); $[\alpha]_D^{20} = -147.9$ ($c = 3.0$, DCM, 98% ee); ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, $J = 8.2$ Hz, 1H), 7.56 – 7.52 (m, 1H), 7.44 – 7.36 (m, 3H), 7.35 – 7.28 (m, 3H), 7.28 – 7.23 (m, 2H), 6.98 – 6.88 (m, 2H), 4.53 (s, 1H), 4.18 (dd, $J = 86.3, 14.4$ Hz, 2H), 2.79 (dd, $J = 105.4, 17.9$ Hz, 2H), 1.95 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 199.0, 194.0, 169.4, 151.9, 137.7, 136.0, 134.0, 132.1, 132.0, 131.7, 129.6, 129.5, 128.9, 128.6, 126.9, 126.5, 116.1, 92.6, 53.1, 35.8, 34.2, 29.7; HRMS (ESI): m/z [M + Na]⁺ calcd for [C₂₇H₂₀BrClNaO₃]⁺: 529.0177, found: 529.0187; HPLC: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, t_{major} = 31.28 min and t_{minor} = 17.28 min.


(2*R*,3*R*)-4-acetyl-5-(2-chlorobenzyl)-6'-methoxy-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'*H*)-one (3ah):



3ah

Followed the general procedure, using **1k** (0.2 mmol, 35.4 mg), **2p** (0.2 mmol, 56.3 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3ah** as a light yellow oil (80.8 mg, 84% yield, >20:1 dr); $[\alpha]_D^{20} = -170.2$ ($c = 3.0$, DCM, 92% ee); **1H NMR** (400 MHz, CDCl_3) δ 7.57 – 7.52 (m, 1H), 7.37 – 7.27 (m, 4H), 7.26 – 7.23 (m, 1H), 7.23 – 7.21 (m, 1H), 7.20 – 7.17 (m, 1H), 7.17 – 7.13 (m, 1H), 7.13 – 7.09 (m, 1H), 7.09 – 7.00 (m, 2H), 4.57 (s, 1H), 4.45 – 4.31 (m, 2H), 3.82 (s, 3H), 2.75 (dd, $J = 93.8, 17.3$ Hz, 2H), 1.92 (s, 3H); **13C NMR** (101 MHz, CDCl_3) δ 200.6, 194.5, 168.2, 159.9, 143.6, 139.3, 134.3, 134.2, 134.0, 130.4, 129.3, 129.1, 128.1, 128.0, 127.0, 127.0, 125.4, 116.9, 106.4, 93.9, 55.7, 54.1, 35.5, 32.1, 29.7; **HRMS** (ESI): m/z [M + Na]⁺ calcd for $[\text{C}_{28}\text{H}_{23}\text{ClNaO}_4]^+$: 481.1177, found: 481.1181; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, $t_{\text{major}} = 37.74$ min and $t_{\text{minor}} = 12.65$ min.


(2*R*,3*R*)-4-acetyl-5'-chloro-5-(3,4-dichlorobenzyl)-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3*H*)-one (3ai):



3ai

Followed the general procedure, using **1c** (0.2 mmol, 36.5 mg), **2s** (0.2 mmol, 63.4 mg) and **L1** (0.02 mmol, 14.0 mg). Purified by flash column chromatography (petroleum ether/ethyl acetate 4:1) to afforded **3ai** as a light yellow oil (81.0 mg, 78% yield, >20:1 dr); $[\alpha]_D^{20} = -156.7$ ($c = 3.0$, DCM, 99% ee); **1H NMR** (400 MHz, CDCl_3) δ 7.75 (d, $J = 8.2$ Hz, 1H), 7.53 – 7.48 (m, 1H), 7.41 – 7.37 (m, 2H), 7.36 – 7.28 (m, 3H), 7.27 – 7.24 (m, 1H), 7.21 – 7.16 (m, 1H), 7.04 – 6.90 (m, 2H), 4.54 (s, 1H), 4.21 – 4.07 (m, 2H), 2.80 (dd, $J = 92.5, 17.9$ Hz, 2H), 1.88 (s, 3H); **13C NMR** (101 MHz, CDCl_3) δ 198.9, 194.8, 167.9, 152.0, 142.8, 138.7, 136.5, 132.4, 131.5, 131.0, 130.8, 130.4, 129.4, 129.2, 128.5, 128.3, 126.6, 126.5, 117.0, 116.1, 93.2, 53.7, 35.9, 33.2, 29.8; **HRMS** (ESI): m/z [M + Na]⁺ calcd for $[\text{C}_{27}\text{H}_{19}\text{Cl}_3\text{NaO}_3]^+$: 519.0292, found: 519.0300; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, $t_{\text{major}} = 14.98$ min and $t_{\text{minor}} = 8.89$ min.


Scale-up reaction



Under a nitrogen atmosphere, a solution of diethylzinc (200 μL , 1.0 M in hexane, 0.2 mmol) was added dropwise to a solution of **L1** (0.1 mmol, 70 mg) in toluene (6 mL). After the mixture was stirred for 30 min at 40 °C. Then, α -hydroxy-1-indanone **1a** (1.0 mmol, 0.15 g), yne-enone **2a** (1.0 mmol, 0.25 g) and 2-Br-4-ClPhOH (0.2 mmol, 41.6 mg) were added. The reaction mixture was stirred for 48 h at 40 °C. The reaction was quenched with NH₄Cl solution (10 mL), and the aqueous layer was extracted with CH₂Cl₂ (3 \times 5 mL). The combined organic layer was washed with brine


and dried over Na_2SO_4 . The solvent was removed under reduced pressure by using a rotary evaporator. The residue was purified by flash chromatography with petroleum ether/ethyl acetate (5/1) to afford the desired product **3a** (0.29 g) as a yellow oil.

The late-stage functionalization




Followed the literature,² the α -bromo- α,β -enone was dissolved in anhydrous THF (0.2 M), followed by addition of $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (0.02 equiv.) and CuI (0.04 equiv.). The reaction mixture was cooled to 0 °C and degassed with argon. Alkyne³ (1.5 equiv.) and Et_3N (3.0 equiv.) was added and the mixture was stirred overnight at ambient temperature. Upon completion, the reaction mixture was diluted with H_2O (40 mL). The aqueous phase was extracted with Et_2O (3 x 40 mL), washed with brine and the combined organic phase was dried over MgSO_4 . Then, it was filtered and the solvent removed.

(8R,9S,13S,14S)-3-(3-((E)-benzylidene)-4-oxopent-1-yn-1-yl)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (2t):




Light yellow solid in 70% isolated yield; **m.p.** = 182.5–183.0 °C; **¹H NMR** (400 MHz, CDCl_3) δ 8.14 – 8.03 (m, 2H), 7.79 (s, 1H), 7.47 – 7.38 (m, 3H), 7.36 – 7.27 (m, 3H), 2.98 – 2.87 (m, 2H), 2.60 (s, 3H), 2.56 – 2.47 (m, 1H), 2.47 – 2.38 (m, 1H), 2.36 – 2.28 (m, 1H), 2.22 – 2.10 (m, 1H), 2.09 – 1.96 (m, 3H), 1.67 – 1.45 (m, 6H), 0.92 (s, 3H); **¹³C NMR** (101 MHz, CDCl_3) δ 220.6, 196.3, 142.5, 141.2, 137.0, 134.6, 131.8, 130.7, 130.7, 128.8, 128.6, 125.7, 120.1, 120.1, 99.4, 86.5, 50.5, 47.9, 44.5, 38.0, 35.8, 31.6, 29.2, 28.2, 26.3, 25.6, 21.6, 13.9; **HRMS (ESI):** m/z [M + H]⁺ calcd for $[\text{C}_{30}\text{H}_{31}\text{O}_2]^+$: 423.2319, found: 423.2321.



Under a nitrogen atmosphere, a solution of diethylzinc (40 μL , 1.0 M in hexane, 0.04 mmol)


was added dropwise to a solution of **L1** (0.02 mmol, 14.0 mg) in toluene (4 mL). After the mixture was stirred for 30 min at 40 °C. Then, α -hydroxy-1-indanone **1d** (0.2 mmol, 45.2 mg), yne-enone **2t** (0.2 mmol, 84.4 mg) and 2-Br-4-ClPhOH (0.04 mmol, 8.28 mg) were added. The reaction mixture was stirred for 48 h at 40 °C. The reaction was quenched with NH₄Cl solution (4 mL), and the aqueous layer was extracted with CH₂Cl₂ (3 × 5 mL). The combined organic layer was washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure by using a rotary evaporator. The residue was purified by flash chromatography with petroleum ether/ethyl acetate (5/1) to afford the desired product **3aj** as a white solid.

(2*R*,3*R*)-4-acetyl-5'-bromo-5-((8*R*,9*S*,13*S*,14*S*)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6*H*-cyclopenta[*a*]phenanthren-3-yl)methyl)-3-phenyl-3*H*-spiro[furan-2,2'-inden]-1'(3'*H*)-one (3aj):




White solid in 80% isolated yield (107.4 mg, >20:1 dr); **m.p.** = 174.6–175.0 °C; [α]_D²⁰ = -38.9 (c = 1.0, DCM, >20:1 de); **¹H NMR** (400 MHz, CDCl₃) δ 7.66 (d, *J* = 8.2 Hz, 1H), 7.52 (d, *J* = 8.2 Hz, 1H), 7.36 – 7.28 (m, 4H), 7.23 (s, 1H), 7.19 – 7.16 (m, 1H), 7.13 (s, 1H), 7.10 – 6.95 (m, 2H), 4.57 (s, 1H), 4.14 (dd, *J* = 48.9, 14.7 Hz, 2H), 2.96 – 2.89 (m, 3H), 2.74 – 2.65 (m, 1H), 2.55 – 2.39 (m, 2H), 2.32 – 2.24 (m, 1H), 2.20 – 1.98 (m, 4H), 1.93 (s, 3H), 1.70 – 1.54 (m, 3H), 1.52 – 1.43 (m, 3H), 0.91 (s, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 221.0, 199.4, 194.4, 169.2, 152.2, 139.2, 138.1, 136.6, 133.5, 132.2, 132.0, 131.6, 129.6, 129.5, 129.2, 128.1, 126.5, 126.2, 125.6, 116.2, 92.8, 53.8, 50.5, 48.0, 44.4, 38.2, 36.0, 35.9, 33.6, 31.6, 29.8, 29.4, 26.6, 25.7, 21.6, 13.9; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₃₉H₃₇BrNaO₄]⁺: 671.1767, found: 671.1776.

Derivatization




The mixture of **3p** (42.8 mg, 0.1 mmol, 1.0 eq) in MeOH (2 mL) was treated with NaBH₄ (3.8 mg, 0.1 mmol, 1.0 eq) at 0 °C. The reaction was allowed to stir at the same temperature for 24 h. Upon completion as shown by TLC, the reaction mixture was washed with brine (2 mL) and extracted using dichloromethane (3 × 2 mL). The organic layer was dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash chromatography with petroleum ether/ethyl acetate (3/1) to provide the product **4** as a yellow oil.

1-((1'R,2R,3R)-5-benzyl-3-(4-chlorophenyl)-1'-hydroxy-1',3'-dihydro-3H-spiro[furan-2,2'-inden]-4-yl)ethan-1-one (4):




4

Light yellow oil in 90% isolated yield (38.8 mg, >20:1 dr); $[\alpha]_D^{20} = -40.4$ ($c = 0.9$, DCM, 98% ee); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.37 – 7.31 (m, 3H), 7.31 – 7.26 (m, 4H), 7.26 – 7.24 (m, 1H), 7.23 – 7.20 (m, 2H), 7.04 – 6.94 (m, 3H), 4.89 (s, 1H), 4.48 – 4.41 (m, 1H), 4.37 (s, 1H), 3.89 – 3.81 (m, 1H), 2.80 – 2.72 (m, 1H), 2.40 – 2.29 (m, 1H), 1.90 (s, 3H), 1.85 (s, 1H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 194.8, 169.6, 141.1, 138.9, 138.5, 136.9, 133.6, 129.2, 128.9, 127.4, 127.2, 124.7, 124.4, 115.9, 112.0, 99.1, 82.5, 54.0, 38.3, 34.1, 29.8; HRMS (ESI): m/z [M + H] $^+$ calcd for $[\text{C}_{27}\text{H}_{24}\text{ClO}_3]^+$: 431.1408, found: 431.1409; **HPLC:** Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, $\lambda = 254$ nm, $t_{\text{major}} = 9.89$ min and $t_{\text{minor}} = 9.00$ min.



The mixture of **4** (43.1 mg, 0.1 mmol, 1.0 eq), Et_3N (15.1 mg, 0.15 mmol, 1.2 eq) and DMAP (1.2 mg, 0.12 mmol, 0.1 eq) in DCM (2 mL) was treated with TsCl (22.9 mg, 0.12 mmol, 1.2 eq) at 0 °C. The reaction was allowed to stir at room temperature for 36 h. Upon completion as shown by TLC, the reaction mixture was washed with saturated NH_4Cl (1 mL) and extracted using dichloromethane (3 x 1 mL). The organic layer was dried over Na_2SO_4 and concentrated in vacuo. The residue was purified by flash chromatography with petroleum ether/ethyl acetate (3/1) to provide the product **5** as a light yellow oil.


(1'R,2R,3R)-4-acetyl-5-benzyl-3-(4-chlorophenyl)-1',3'-dihydro-3H-spiro[furan-2,2'-inden]-1'-yl 4-methylbenzenesulfonate (5):



5


Light yellow oil in 75% isolated yield (45.5 mg, >20:1 dr); $[\alpha]_D^{20} = -152.6$ ($c = 2.0$, DCM, 98% ee); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.77 – 7.62 (m, 2H), 7.30 – 7.27 (m, 3H), 7.24 – 7.16 (m, 5H), 7.15 – 7.03 (m, 4H), 6.90 (d, $J = 7.2$ Hz, 1H), 6.67 (d, $J = 8.4$ Hz, 2H), 5.79 (s, 1H), 4.37 – 4.26 (m, 1H), 4.06 (s, 1H), 3.58 – 3.49 (m, 1H), 2.84 – 2.73 (m, 1H), 2.39 (s, 3H), 2.34 – 2.27 (m, 1H), 1.81 (s,

3H). **¹³C NMR** (101 MHz, CDCl₃) δ 194.1, 170.3, 145.1, 139.7, 137.9, 136.3, 136.2, 133.8, 133.6, 129.9, 129.2, 129.1, 128.5, 127.9, 127.7, 126.8, 125.7, 124.8, 115.5, 96.6, 86.5, 54.3, 37.9, 34.0, 29.6, 21.7; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₃₄H₂₉ClNaO₅S]⁺: 607.1316, found: 607.1326; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, t_{major} = 18.78 min and t_{minor} = 14.75 min.



The mixture of **4** (43.1 mg, 0.1 mmol, 1.0 eq), Et₃N (15.2 mg, 0.15 mmol, 1.2 eq), and DMAP (1.2 mg, 0.12 mmol, 0.1 eq) in DCM (2 mL) was treated with 3,5-dinitrobenzoyl chloride (27.6 mg, 0.12 mmol, 1.2 eq) at 0 °C. The reaction was allowed to stir at room temperature for 24 h. Upon completion as shown by TLC, the reaction mixture was washed with saturated NH₄Cl (1 mL) and extracted using dichloromethane (3 x 1 mL). The organic layer was dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash chromatography with petroleum ether/ethyl acetate (3/1) to provide the product **6** as a white solid.

(1'R,2R,3R)-4-acetyl-5-benzyl-3-(4-chlorophenyl)-1',3'-dihydro-3*H*-spiro[furan-2,2'-inden]-1'-yl 3,5-dinitrobenzoate (6):



6


White solid in 80% isolated yield (51.8 mg, >20:1 dr); **m.p.** = 188.1–189.1 °C; [α]_D²⁰ = -190.8 (c = 2.3, DCM, 97% ee); **¹H NMR** (400 MHz, CDCl₃) δ 9.19 – 9.13 (m, 1H), 8.88 – 8.77 (m, 2H), 7.54 (d, *J* = 6.9 Hz, 1H), 7.48 – 7.21 (m, 5H), 7.19 (d, *J* = 7.3 Hz, 2H), 7.06 (d, *J* = 7.2 Hz, 1H), 6.96 – 6.91 (m, 2H), 6.79 – 6.74 (m, 1H), 6.27 (s, 1H), 4.47 – 4.32 (m, 1H), 4.13 (s, 1H), 3.96 – 3.84 (m, 1H), 3.35 – 3.22 (m, 1H), 2.53 – 2.41 (m, 1H), 1.95 (s, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 194.5, 169.9, 161.9, 148.4, 141.4, 136.8, 136.3, 136.2, 133.9, 133.3, 130.6, 129.4, 128.8, 128.2, 127.9, 127.2, 126.3, 125.1, 122.3, 115.9, 95.2, 81.1, 55.0, 37.0, 34.1, 29.6; **HRMS** (ESI): m/z [M + Na]⁺ calcd for [C₃₄H₂₅ClNaO₈]⁺: 647.1192, found: 647.1199; **HPLC**: Daicel Chiralpak IC, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1 mL/min, λ = 254 nm, t_{major} = 52.94 min and t_{minor} = 47.56 min.

References


1. Matsuo, K.; Shindo, M. Cu(II)-Catalyzed Acylation by Thiol Esters Under Neutral Conditions: Tandem Acylation-Wittig Reaction Leading to a One-Pot Synthesis of Butenolides. *Org. Lett.*, **2010**, *12*, 5346–5349.
2. Poulsen, P. H.; Li, Y.; Lauridsen, V. H.; Jørgensen, D. K. B.; Palazzo, T. A.; Meazza, M.; Jørgensen, K. A. Organocatalytic Formation of Chiral Trisubstituted Allenes and Chiral Furan Derivatives. *Angew. Chem. Int. Ed.*, **2018**, *57*, 10661–10665.
3. Guo, H. Y., Zhang, S., Yu, X. Q., Feng, X. J., Yamamoto, Y., Bao, M. [3 + 2] Cycloaddition of α -Aryl- α -diazoacetates with Terminal Alkynes via the Cooperative Catalysis of Palladium and Acid. *ACS Catalysis*, **2021**, *11*, 10789-10795.

NMR Spectra of compounds


¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹⁹F NMR (376 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹⁹F NMR (376 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




3n




¹³C NMR (101 MHz, CDCl₃)




3n




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)





¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)






¹H NMR (400 MHz, CDCl₃)






¹³C NMR (101 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)




¹³C NMR (101 MHz, CDCl₃)





^1H NMR (400 MHz, CDCl_3)




3v




¹³C NMR (101 MHz, CDCl₃)




3v




^1H NMR (400 MHz, CDCl_3)




¹³C NMR (101 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)




3x




¹³C NMR (101 MHz, CDCl₃)




3x




¹H NMR (400 MHz, CDCl₃)




3y
10:1 dr




¹³C NMR (101 MHz, CDCl₃)




3y
10:1 dr




^1H NMR (400 MHz, CDCl_3)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




^1H NMR (400 MHz, CDCl_3)




3ad




¹³C NMR (101 MHz, CDCl₃)




3ad




^1H NMR (400 MHz, CDCl_3)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




HPLC spectra of compounds







↔ ↔ ♦ ♦ ✎ 0


Integration Result		Calculation Result		TimeTable	
No.	Retention Time	Peak Area	Peak Height	PeakArea(%)	Peak Width
1	11.33	220670	11694	49.97%	1.403 BB
2	21.74	220955	6073	50.03%	1.731 BB
Total		441,625	17,767	100.00%	



↔ ↔ ♦ ♦ ✎ 0

Integration Result		Calculation Result		TimeTable	
No.	Retention Time	Peak Area	Peak Height	PeakArea(%)	Peak Width
1	11.26	239300	12591	1.31%	1.031 BB
2	21.35	18089617	530716	98.69%	2.825 BB
Total		18,328,917	543,307	100.00%	






↔ * ♦ ♣ ♠ 0

[Integration Result](#) | [Calculation Result](#) | [TimeTable](#) |



No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	14.14	262778	10139	49.99%	2.038 BB
2	29.72	262836	4767	50.01%	2.887 BB
Total		525,614	14,906	100.00%	




↔ * ♦ ♣ ♠ 0


[Integration Result](#) | [Calculation Result](#) | [TimeTable](#) |

No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	14.15	31829	1397	1.03%	1.423 BB
2	29.59	3066218	53087	98.97%	4.752 BB
Total		3,098,047	54,484	100.00%	











Integration Result						
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	
1	22.81	278757	6069	49.92%	3.577 BB	
2	62.08	279654	2305	50.08%	5.903 BB	
Total		558,411	8,374	100.00%		





Integration Result						
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	
1	22.59	31353	925	1.19%	2.565 BB	
2	61.12	2612968	21592	98.81%	8.501 BB	
Total		2,644,321	22,517	100.00%		














Integration Result | Calculation Result | TimeTable |



No.	Retention Time	Peak Area	Peak Height	PeakArea(%)	Peak Width
1	14.32	981253	36892	49.95%	1.743 BB
2	45.57	983053	11050	50.05%	3.95 BB
Total		1,964,306	47,942	100.00%	






Integration Result | Calculation Result | TimeTable |

No.	Retention Time	Peak Area	Peak Height	PeakArea(%)	Peak Width
1	14.44	156364	5592	1.12%	1.634 BB
2	45.15	13760880	145949	98.88%	5.778 BB
Total		13,917,244	151,541	100.00%	


















Integration Result Calculation Result TimeTable					
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	13.50	306116	12593	50.10%	1.41 BB
2	31.23	304834	5202	49.90%	2.997 BB
Total		610,950	17,795	100.00%	







Integration Result Calculation Result TimeTable					
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	14.12	150307	6598	1.28%	1.032 BB
2	31.25	11564114	200611	98.72%	4.168 BB
Total		11,714,421	207,209	100.00%	
















Integration Result		Calculation Result		TimeTable	
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	18.68	367643	10976	49.88%	2.302 BB
2	27.82	369367	7085	50.12%	3.563 BB
Total		737,010	18,061	100.00%	




Integration Result		Calculation Result		TimeTable	
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	18.73	285124	8623	5.52%	1.488 BB
2	27.71	4884598	94837	94.48%	3.584 BB
Total		5,169,722	103,460	100.00%	



↔ * ♫ * ♪ 0

Integration Result | Calculation Result | TimeTable |


No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	14.20	1579784	64265	49.87%	1.039 BB
2	29.80	1587824	29639	50.13%	2.314 BB
Total		3,167,608	93,904	100.00%	




↔ * ♫ * ♪ 0

Integration Result | Calculation Result | TimeTable |


No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	13.78	172896	6598	3.42%	1.33 BB
2	28.91	4884591	93297	96.58%	3.909 BB
Total		5,057,487	99,895	100.00%	



Integration Result						
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	
1	11.53	257930	13342	18.39%	0.97	BV
2	12.45	454544	22700	32.41%	1.158	VB
3	20.40	245979	7075	17.54%	2.129	BB
4	23.45	444196	11574	31.67%	2.255	BB
Total		1,402,649	54,691	100.00%		




Integration Result						
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	
1	11.43	26360	1721	0.42%	0.639	BB
2	12.34	31468	2198	0.51%	0.998	BB
3	20.17	2280065	67260	36.75%	2.078	BB
4	23.17	3866186	102814	62.32%	2.438	BB
Total		6,204,079	173,993	100.00%		




Integration Result | Calculation Result | TimeTable |

No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	46.66	901086	11147	49.56%	3.845 BV
2	51.11	917132	10469	50.44%	4.72 VB
Total		1,818,218	21,616	100.00%	



Integration Result | Calculation Result | TimeTable |


No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	46.57	633753	7880	98.77%	4.893 BB
2	50.78	7860	150	1.23%	2.681 BB
Total		641,613	8,030	100.00%	



↔ ↔ ♦ ♦ ♦ 0

Integration Result | Calculation Result | TimeTable |


No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	12.45	250716	10326	9.49%	1.635 BB
2	17.56	265743	6564	10.06%	1.545 BV
3	19.16	1071575	27108	40.58%	2.111 VB
4	23.57	1052665	20346	39.86%	3.063 BB
Total		2,640,699	64,344	100.00%	



↔ ↔ ♦ ♦ ♦ 0


Integration Result | Calculation Result | TimeTable |

No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	13.62	42240	1518	0.27%	1.388 BB
2	17.56	1000482	25233	6.29%	1.537 BV
3	18.90	14809820	388143	93.04%	3.187 VB
4	23.60	64736	1440	0.41%	1.688 BB
Total		15,917,278	416,334	100.00%	





↔ ↔ ↔ * + 0


Integration Result		Calculation Result		TimeTable	
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	6.12	329937	31367	9.26%	0.733 BB
2	7.44	1454221	117280	40.79%	0.572 BV
3	8.02	438833	34450	12.31%	0.537 VB
4	9.49	1341948	87119	37.64%	0.823 BB
Total		3,564,939	270,216	100.00%	



↔ ↔ ↔ * + 0


Integration Result		Calculation Result		TimeTable	
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	6.03	508334	50982	15.49%	0.511 BB
2	7.33	67583	5414	2.06%	0.7 BB
3	8.75	200963	13468	6.13%	0.551 BV
4	9.34	2504123	162470	76.32%	0.877 VB
Total		3,281,003	232,334	100.00%	







↔ ↔ ♦ ♦ ♦ 0


Integration Result Calculation Result TimeTable					
No.	Retention Time	PeakArea	Peak Height	Peak Area(%)	Peak Width
1	25.20	972822	20075	50.08%	1.889 BB
2	43.22	969802	11280	49.92%	5.289 BB
Total		1,942,624	31,355	100.00%	



↔ ↔ ♦ ♦ ♦ 0

Integration Result Calculation Result TimeTable					
No.	Retention Time	PeakArea	Peak Height	Peak Area(%)	Peak Width
1	25.21	145874	3006	2.09%	2.458 BB
2	42.66	6841055	80231	97.91%	5.875 BB
Total		6,986,929	83,237	100.00%	






↔ ↔ ♦ ♦ ✕ ✕ 0

Integration Result | Calculation Result | TimeTable |


No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	11.04	1591856	83551	50.16%	0.938 BB
2	21.69	1581675	39498	49.84%	2.243 BB
Total		3,173,531	123,049	100.00%	




↔ ↔ ♦ ♦ ✕ ✕ 0

Integration Result | Calculation Result | TimeTable |


No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	11.16	168390	8756	2.33%	0.972 BB
2	21.77	7053813	177199	97.67%	2.518 BB
Total		7,222,203	185,955	100.00%	



Integration Result		Calculation Result		TimeTable	
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	13.41	1743649	86542	50.05%	0.826 BB
2	30.35	1740160	33844	49.95%	2.355 BB
Total		3,483,809	120,386	100.00%	




Integration Result		Calculation Result		TimeTable	
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	13.43	32119	1677	1.60%	1.548 BB
2	30.73	1979628	37501	98.40%	4.361 BB
Total		2,011,747	39,178	100.00%	



↔ ↔ ♦ ♦ ✎ ✎ 0

Integration Result | Calculation Result | TimeTable |


No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	8.38	1449654	92504	49.64%	1.581 BB
2	19.72	1470668	38500	50.36%	1.946 BB
Total		2,920,322	131,004	100.00%	



↔ ↔ ♦ ♦ ✎ ✎ 0


Integration Result | Calculation Result | TimeTable |

No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	8.37	197552	12243	1.88%	1.015 BB
2	20.38	10329043	254947	98.12%	2.661 BB
Total		10,526,595	267,190	100.00%	





↔ ↔ ♦ ♦ ✪ ✪ 0



Integration Result		Calculation Result		TimeTable	
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	16.99	1463563	32212	49.96%	4.265 BB
2	31.64	1465654	19035	50.04%	4.069 BB
Total		2,929,217	51,247	100.00%	




↔ ↔ ♦ ♦ ✪ ✪ 0

Integration Result		Calculation Result		TimeTable	
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	17.28	40779	907	1.13%	1.807 BB
2	31.28	3571309	46553	98.87%	6.191 BB
Total		3,612,088	47,460	100.00%	








↔ ↔ ♫ ♪ ♫ ♪ 0

Integration Result | Calculation Result | TimeTable |


No.	Retention Time	Peak Area	Peak Height	PeakArea(%)	Peak Width
1	9.03	152518	8291	50.28%	0.658 BV
2	9.91	150849	6644	49.72%	1.223 VB
Total		303,367	14,935	100.00%	




↔ ↔ ♫ ♪ ♫ ♪ 0

Integration Result | Calculation Result | TimeTable |



No.	Retention Time	Peak Area	Peak Height	PeakArea(%)	Peak Width
1	9.00	7152	472	1.15%	0.491 BV
2	9.89	617248	26184	98.85%	2.148 VB
Total		624,400	26,656	100.00%	



Integration Result		Calculation Result		TimeTable	
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	14.42	380746	11185	50.15%	1.319 BB
2	18.41	378500	8274	49.85%	2.638 BB
Total		759,246	19,459	100.00%	




Integration Result		Calculation Result		TimeTable	
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	14.75	15380	393	1.20%	1.602 BB
2	18.78	1270326	27059	98.80%	3.308 BB
Total		1,285,706	27,452	100.00%	



Single-crystal X-ray diffraction of 6 (CCDC 2247366)

X-ray analysis was carried out using the single crystal which was grown in Hexane/acetone.

The instrumentation used for the crystal measurement is Oxford Gemini E X-ray single-crystal diffractometer (ellipsoid contour at 30% probability level).



6

Datablock: 20230229

Bond precision:	C-C = 0.0059 Å	Wavelength=1.54184
Cell:	a=15.7718 (3)	b=14.18227 (19)
	alpha=90	beta=115.571 (2)
Temperature:	293 K	gamma=90
	Calculated	Reported
Volume	3370.82 (11)	3370.80 (11)
Space group	P 21	P 1 21 1
Hall group	P 2yb	P 2yb
Moiety formula	C ₃₄ H ₂₅ Cl N ₂ O ₈ [+ solvent]	1(C ₃₄ H ₂₅ Cl N ₂ O ₈)
Sum formula	C ₃₄ H ₂₅ Cl N ₂ O ₈ [+ solvent]	C ₃₄ H ₂₅ Cl N ₂ O ₈
Mr	625.01	625.01
Dx, g cm ⁻³	1.232	1.232
Z	4	4
Mu (mm ⁻¹)	1.435	1.435
F000	1296.0	1296.0
F000'	1301.58	
h,k,lmax	19,17,20	19,17,20
Nref	13011 [6787]	12736
Tmin, Tmax	0.799, 0.866	0.915, 1.000
Tmin'	0.795	

Correction method= # Reported T Limits: Tmin=0.915 Tmax=1.000
AbsCorr = MULTI-SCAN

Data completeness= 1.88/0.98 Theta(max)= 70.964

R(reflections) = 0.0477(10785)	wR2(reflections) = 0.1358(12736)
S = 1.028	Npar= 807

The following ALERTS were generated. Each ALERT has the format
test-name_ALERT_alert-type_alert-level.
Click on the hyperlinks for more details of the test.

● Alert level C

PLAT234_ALERT_4_C Large Hirshfeld Difference C10 --C11 . 0.16 Ang.	C25' Check
PLAT242_ALERT_2_C Low 'MainMol' Ueq as Compared to Neighbors of	C20 Check
PLAT242_ALERT_2_C Low 'MainMol' Ueq as Compared to Neighbors of	C25 Check
PLAT242_ALERT_2_C Low 'MainMol' Ueq as Compared to Neighbors of	C25 Check
PLAT334_ALERT_2_C Small <C-C> Benzene Dist. C22 -C27 . 1.37 Ang.	
PLAT334_ALERT_2_C Small <C-C> Benzene Dist. C29 -C34 . 1.37 Ang.	
PLAT340_ALERT_3_C Low Bond Precision on C-C Bonds	0.00588 Ang.

● Alert level G

PLAT002_ALERT_2_G Number of Distance or Angle Restraints on AtSite	13 Note
PLAT003_ALERT_2_G Number of Uiso or Uij Restrained non-H Atoms ...	13 Report
PLAT171_ALERT_4_G The CIF-Embedded .res File Contains EADP Records	13 Report
PLAT172_ALERT_4_G The CIF-Embedded .res File Contains DFIX Records	8 Report
PLAT186_ALERT_4_G The CIF-Embedded .res File Contains ISOR Records	3 Report
PLAT199_ALERT_1_G Reported _cell_measurement_temperature (K)	293 Check
PLAT200_ALERT_1_G Reported _diffrn_ambient_temperature (K)	293 Check
PLAT301_ALERT_3_G Main Residue Disorder(Resd 1)	22% Note
PLAT301_ALERT_3_G Main Residue Disorder(Resd 2)	7% Note
PLAT398_ALERT_2_G Deviating C-O-C Angle From 120 for O1'	. 106.6 Degree
PLAT398_ALERT_2_G Deviating C-O-C Angle From 120 for O1	. 107.1 Degree
PLAT431_ALERT_2_G Short Inter HL..A Contact C11' ..07'	. 3.14 Ang.
x,y,1+z = 1_556	Check
PLAT606_ALERT_4_G Solvent Accessible VOID(S) in Structure	! Info
PLAT720_ALERT_4_G Number of Unusual/Non-Standard Labels	7 Note
PLAT721_ALERT_1_G Bond Calc 0.96000, Rep 0.97000 Dev... C1A -H1AA 1_555 1_555	0.01 Ang. # 80 Check
PLAT791_ALERT_4_G Model has Chirality at C3	(Sohnke SpGr) R Verify
PLAT791_ALERT_4_G Model has Chirality at C3'	(Sohnke SpGr) S Verify
PLAT791_ALERT_4_G Model has Chirality at C4	(Sohnke SpGr) R Verify
PLAT791_ALERT_4_G Model has Chirality at C4'	(Sohnke SpGr) R Verify
PLAT791_ALERT_4_G Model has Chirality at C5	(Sohnke SpGr) R Verify
PLAT791_ALERT_4_G Model has Chirality at C5'	(Sohnke SpGr) R Verify
PLAT860_ALERT_3_G Number of Least-Squares Restraints	87 Note
PLAT910_ALERT_3_G Missing # of FCF Reflection(s) Below Theta(Min).	3 Note
PLAT912_ALERT_4_G Missing # of FCF Reflections Above STh/L= 0.600	51 Note
PLAT941_ALERT_3_G Average HKL Measurement Multiplicity	4.0 Low
PLAT978_ALERT_2_G Number C-C Bonds with Positive Residual Density.	0 Info

0 **ALERT level A** - Most likely a serious problem - resolve or explain
0 **ALERT level B** - A potentially serious problem, consider carefully
7 **ALERT level C** - Check. Ensure it is not caused by an omission or oversight
26 **ALERT level G** - General information/check it is not something unexpected

3 ALERT type 1 CIF construction/syntax error, inconsistent or missing data
11 ALERT type 2 Indicator that the structure model may be wrong or deficient
6 ALERT type 3 Indicator that the structure quality may be low
13 ALERT type 4 Improvement, methodology, query or suggestion
0 ALERT type 5 Informative message, check

It is advisable to attempt to resolve as many as possible of the alerts in all categories. Often the minor alerts point to easily fixed oversights, errors and omissions in your CIF or refinement strategy, so attention to these fine details can be worthwhile. In order to resolve some of the more serious problems it may be necessary to carry out additional measurements or structure refinements. However, the purpose of your study may justify the reported deviations and the more serious of these should normally be commented upon in the discussion or experimental section of a paper or in the "special_details" fields of the CIF. checkCIF was carefully designed to identify outliers and unusual parameters, but every test has its limitations and alerts that are not important in a particular case may appear. Conversely, the absence of alerts does not guarantee there are no aspects of the results needing attention. It is up to the individual to critically assess their own results and, if necessary, seek expert advice.

Publication of your CIF in IUCr journals

A basic structural check has been run on your CIF. These basic checks will be run on all CIFs submitted for publication in IUCr journals (*Acta Crystallographica*, *Journal of Applied Crystallography*, *Journal of Synchrotron Radiation*); however, if you intend to submit to *Acta Crystallographica Section C* or *E* or *IUCrData*, you should make sure that full publication checks are run on the final version of your CIF prior to submission.

Publication of your CIF in other journals

Please refer to the *Notes for Authors* of the relevant journal for any special instructions relating to CIF submission.

PLATON version of 28/11/2022; check.def file version of 28/11/2022